In another recent study involving 318 CU participants, including 158 individuals who later converted to AD and 160 who remained cognitively unimpaired, the authors observed elevated plasma levels of GFAP in AD-converters up to 10 years before the onset of cognitive impairment [119]. This evidence concerns the gene GFAP and Alzheimer disease.